

A central role for dityrosine crosslinking of Amyloid- β in Alzheimer's disease

Article (Published Version)

Al-Hilaly, Youssra K, Williams, Thomas L, Stewart-Parker, Maris, Ford, Lenzie, Skaria, Eldhose, Cole, Michael, Bucher, William, Morris, Kyle L, Sada, Alaa, Thorpe, Julian R and Serpell, Louise C (2013) A central role for dityrosine crosslinking of Amyloid- β in Alzheimer's disease. *Acta Neuropathologica Communications*, 1 (83). pp. 1-17. ISSN 2051-5960

This version is available from Sussex Research Online: <http://sro.sussex.ac.uk/id/eprint/48320/>

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:

Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

RESEARCH

Open Access

A central role for dityrosine crosslinking of Amyloid- β in Alzheimer's disease

Youssra K Al-Hilaly^{1,2}, Thomas L Williams³, Maris Stewart-Parker¹, Lenzie Ford¹, Eldhose Skaria¹, Michael Cole¹, William Grant Bucher¹, Kyle L Morris^{1,4}, Alaa Abdul Sada¹, Julian R Thorpe¹ and Louise C Serpell^{1*}

Abstract

Background: Alzheimer's disease (AD) is characterized by the deposition of insoluble amyloid plaques in the neuropil composed of highly stable, self-assembled Amyloid-beta ($A\beta$) fibrils. Copper has been implicated to play a role in Alzheimer's disease. Dimers of $A\beta$ have been isolated from AD brain and have been shown to be neurotoxic.

Results: We have investigated the formation of dityrosine cross-links in $A\beta_{42}$ formed by covalent ortho-ortho coupling of two tyrosine residues under conditions of oxidative stress with elevated copper and shown that dityrosine can be formed in vitro in $A\beta$ oligomers and fibrils and that these links further stabilize the fibrils. Dityrosine crosslinking was present in internalized $A\beta$ in cell cultures treated with oligomeric $A\beta_{42}$ using a specific antibody for dityrosine by immunogold labeling transmission electron microscopy. Results also revealed the prevalence of dityrosine crosslinks in amyloid plaques in brain tissue and in cerebrospinal fluid from AD patients.

Conclusions: $A\beta$ dimers may be stabilized by dityrosine crosslinking. These results indicate that dityrosine cross-links may play an important role in the pathogenesis of Alzheimer's disease and can be generated by reactive oxygen species catalyzed by Cu^{2+} ions. The observation of increased $A\beta$ and dityrosine in CSF from AD patients suggests that this could be used as a potential biomarker of oxidative stress in AD.

Keywords: Amyloid, Oligomer, Aggregation, Alzheimer's disease, Dityrosine, Oxidative stress, Electron microscopy

Background

Amyloid fibrils are associated with a large number of diseases in which proteins or peptides abnormally assemble to form insoluble amyloid deposits in the tissues. The amyloid- β ($A\beta$) protein is an amyloidogenic peptide that is cleaved from the amyloid precursor protein (APP) [1]. The $A\beta$ peptide is present in all individuals but in Alzheimer's disease (AD) it abnormally assembles and deposits in amyloid plaques in the neuropil [1]. Amyloid fibrils are characterized by their significant insolubility and resistance to degradation [2]. $A\beta$ is thought to play a central role in AD pathology since several familial AD mutations are related to changes within the $A\beta$ peptide itself, or in the proteins affecting its production [3]. $A\beta_{42}$ contains a tyrosine at position 10, located close to the fibrillogenic core of the peptide [4]. However, the tyrosine

residue can oxidize to many different modification products, such as nitrotyrosine and dityrosine [5].

Redox-active metal ions, such as Cu^{2+} and Fe^{3+} , have been suggested to play a role in the pathogenesis of many neurodegenerative disorders, including AD and Parkinson's disease [6]. There is a large body of evidence pointing to the importance of interactions between redox-active metal ions and proteins in the pathogenesis of many diseases [7-9]. Two mechanisms have been suggested to explain the abnormalities of these interactions in neural tissue: (a) the aggregation of protein mediated by redox-active metal ions; and (b) metal catalyzed oxidation reactions (MCO) [10]. Metal-protein interactions could result in oxidative stress through generation of reactive-oxygen species (ROS), which in turn induces lipid peroxidation, protein oxidation, and DNA damage [11,12]. The consequences of protein oxidation are protein cross-links, amino acid side chain modifications, and protein fragmentation [11,13]. The oxidative modification of proteins by ROS has been classified in two groups; (a) Global oxidative modifications, which include

* Correspondence: L.C.Serpell@sussex.ac.uk

¹School of Life Sciences, University of Sussex, Falmer BN1 9QG, UK
Full list of author information is available at the end of the article

oxidation of multiple residues within protein to form several products; (b) Specific oxidative modifications which are very specific in both the residue oxidized and the product generated, e.g. oxidation of tyrosine residue to give dityrosine [14].

High concentrations of copper (0.4 mM), zinc (1 mM), and iron (1 mM) have been found in amyloid plaques and have been implicated in the pathogenesis of AD [10,15]. Several studies have shown that A β is able to reduce copper and iron ions and to generate ROS [7,9,12,16]. The most common *in vivo* source of ROS is hydrogen peroxide (H₂O₂) breakdown according to the Fenton reaction, which is catalyzed by a metal-protein complex [7].

The formation of dityrosine cross-links is one of the oxidative modifications that have been implicated in mediating toxicity of A β through A β aggregation. Several studies [17-20] demonstrate that A β can undergo dityrosine formation via two common biochemical pathways. One of them is peroxidase-catalyzed cross-linked tyrosine and the second mechanism is metal-catalyzed oxidative tyrosyl radical formation. The mechanism of dityrosine cross-links involves tyrosyl radical formation, followed by radical isomerisation and then diradical reaction, and finally enolisation [21]. On the other hand, Smith et al. demonstrated that the generation of the A β toxic species is modulated by the concentration of Cu²⁺ ions and the ability to form intermolecular histidine bridges [22]. Interestingly dityrosine has been selected as a biomarker for oxidative stress of proteins due to its chemical stability, as it remains unchanged by exposure to oxygen and high pH [23]. Furthermore, it is highly resistant to acid hydrolysis and proteases [24,25].

Here we have explored the *in vitro* formation of dityrosine in A β 42 using Cu²⁺ ions and H₂O₂ in both early oligomeric A β 42 and preformed A β 42 fibrils and examined the effect of the cross-linking on the structure of the fibrils and the assembly competence of the oligomers. We have shown that dityrosine formation is inducible in both soluble and fibrillar A β 42 and suggest that the formation of crosslinks may stabilize assemblies. Neuroblastoma cell cultures treated with non-oxidized A β 42 oligomers showed formation of A β assemblies containing dityrosine surrounding and sometimes internalized into the cells. Examination of samples from AD patients revealed the presence of dityrosine linkages within amyloid plaques and its colocalisation with A β in cerebrospinal fluid pointing to a physiological relevance of dityrosine cross-linking in AD, and highlighting the importance of oxidative stress in the disease.

Methods

Synthesis of a dityrosine standard

A dityrosine standard was synthesized according to modifications of established procedures [20,26]. 20 units of

horse radish peroxidase (HRP) were added to a clear solution of (10 mM) *N*-acetyl-3,5-diiodo-L-tyrosine in 40 ml of (0.1 M) phosphate buffer pH 6.0 containing 10% of acetonitrile then mixed gently. Immediately, 0.48 ml of (1 M) H₂O₂ was added then the reaction mixture was stirred gently for 60 min at 24°C, quenched with 1.2 ml of (1 M) NaHSO₃ and the pH of the mixture was adjusted to 7.5 with (1 M) NaOH. After stirring for 10 min the mixture was acidified to pH 3.0 with (2 M) KHSO₄ and then extracted with ethyl acetate. The combined organic residues were concentrated under vacuum to give a tan residue, which was purified by flash chromatography to give 3,3'-diiodo-*N,N'*-diacetyl di-L-tyrosine. In turn, 3,3'-diiodo-*N,N'*-diacetyl di-L-tyrosine was hydrogenated in 50% methanol:acetic acid to give *N,N'*-diacetyl di-L-tyrosine, which was heated at reflux in a 1:1 mixture of tetrahydrofuran and concentrated HCl to give dityrosine. Gel filtration on sephadex G-10 was carried out in order to remove the salt and further purification was achieved using RP-HPLC. Finally, the purified dityrosine was dried using a freeze dryer (Edwards, England), and analyzed using a Bruker Daltonics APEX III 4.7 Tesla Fourier Transform ion cyclotron resonance mass spectrometer (FT-ICR-MS) with electrospray source and found to be *m/z* 361.1392 compared with calculated *m/z* 361.1394. NMR was carried out and the ¹H NMR spectrum contained six proton signals with chemical shifts of: 7.30 ppm (H, d), 7.21 ppm (H, s), 7.07 ppm (H, d), 4.26 ppm (H, m), 3.35 ppm (H, dd), and 3.26 ppm (H', dd). This spectrum is very similar to that published elsewhere [27-29].

Preparation of fibrillar and oligomeric A β 42

1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) A β 42 was purchased from rPeptide (Bogart, GA, USA). To remove preformed aggregates, the peptide was prepared as previously described [30] using HFIP >99.0%, followed by anhydrous DMSO (Fisher Sci.) and then buffer exchanged using a desalting column to remove the solvents. The concentration was determined using a molar extinction coefficient of 1490 M⁻¹ cm⁻¹ and the absorbance was measured at a wavelength of 280 nm using an Eppendorf Biophotometer (Eppendorf UK Ltd., Cambridge, UK). The resulting stock peptide concentrations of 90–130 μ M were used immediately for early oligomeric A β 42 experiments, or incubated for at least two weeks at room temperature (22°C) in order to generate A β 42 fibrils (confirmed using TEM).

Oxidation of fibrillar and early oligomeric A β 42

Stock solutions of soluble or fibrillar A β 42 were diluted in (a) water or (b) 50 mM phosphate buffer pH 7.4 to obtain 20 μ M A β 42 as a final concentration and incubated with or without (20 μ M) Cu²⁺ and (0.5 mM) H₂O₂ at 37°C with agitation in a shaking incubator for three

days. The oxidation reaction was quenched using a final concentration of 250 μ M EDTA.

Fluorescence spectroscopy

The fibrils were resuspended by agitation. Fluorescence spectra were recorded over time. Fluorescence measurements were carried out on a Varian Cary Eclipse fluorimeter (Varian Ltd., Oxford, UK) using a 1 cm path length quartz cuvette (Starna, Essex, UK), and dityrosine fluorescence was monitored using an excitation wavelength of 320 nm. Dityrosine emission was monitored between 340 and 500 nm, with maximum fluorescence intensity at around 400–420 nm at a controlled temperature of 21°C. Tyrosine fluorescence signal was monitored using an excitation wavelength of 280 nm and emission wavelength of 305 nm. Excitation and emission slits were both set to 10 nm, and the scan rate was set to 300 nm/min with 2.5 nm data intervals and an averaging time of 0.5 s. The photomultiplier tube detector voltage was set at 500 V. To detect dityrosine fluorescence at early time points, 130 μ l of the reaction mixture was removed and EDTA was added to final concentration of 250 μ M.

Sample preparation for LC-ESIMS/MS analysis

Oxidized A β 42 fibrils prepared in water were lyophilized using a Modulyo 4 K Freeze Dryer (Edwards, Crawley, England), and then hydrolysed using evacuated sealed tubes under acidic conditions of (6 M) HCl, 10% TFA, and 1% phenol at 110°C for 48 h. The resulting hydrolysate was then dried under nitrogen gas, dissolved in 100 μ l of 0.1% formic acid in water and then filtered using a Millipore 0.22 μ m filter into a 0.2 ml tube.

Detection of dityrosine by LC-ESIMS/MS

20 μ l of oxidized A β 42 fibril hydrolysate was injected on to a Phenomenex Gemini 3u C₆-phenyl 110 (150 mm \times 4.6 mm, 3 micron) column using a High performance liquid chromatography (HPLC) system (Waters Alliance 2695, Ireland) coupled to the mass spectrometer (Micro-Mass Quattro Premier, Waters, Ireland) operated in the multiple reaction-monitoring (MRM) mode with positive electrospray ionisation (ESI). The solvents for the mobile phase were A: 0.1% formic acid in water; and solvent B: 0.1% formic acid in acetonitrile. The gradients were as follows: t = 0 min, 0% B; t = 1 min, 0% B; t = 15 min, 100% B; t = 20 min, 100% B; t = 25 min, 0% B; t = 30 min, 0% B, and the flow rate was 200 μ l/min. Mass spectrometric detection was performed by positive electrospray ionisation (ESI) tandem mass spectrometry on a triple quadrupole mass spectrometer (MicroMass Quattro Premier, Waters, Ireland). The conditions for the mass spectrometer were as follows; electrospray ionization spray voltage 3.5 kV, the cone voltage 35 V, the source temperature at 100°C, whereas the desolvation temperature was 400°C. Argon

was used as the collision gas at 5.95 \times 10⁻³ mbar at 26 eV collision energy.

Thioflavin T fluorescence assay

The fibril formation of A β 42 was monitored using ThT fluorescence. A 0.2 μ M filtered (3.14 mM) aqueous ThT stock solution was prepared and stored frozen at -20°C in 1–10 μ l aliquots until required. ThT was added to a 10 μ M A β 42 sample (50 mM phosphate buffer pH 7.4) to a final concentration of 20 μ M, gently vortexed, and allowed to bind for 3 minutes before a reading was taken. Using a microvolume cuvette of 1 cm path length, ThT fluorescence was measured using a Varian Cary Eclipse fluorimeter (Varian, Oxford, UK) with excitation wavelength of 450 nm. The emission spectrum was recorded between 460–600 nm at 21°C. Phosphate buffer baselines were subtracted from the data. Excitation and emission slits were set to 5 nm and 10 nm respectively. The scan rate was 600 nm/min with 1 nm data intervals and an averaging time of 0.1 s. The voltage on the photomultiplier tube was set to high (800 v) and experiments were carried out in triplicate to confirm trends.

Negative stain TEM

Four microliter aliquots of A β 42 samples were placed onto Formvar/carbon coated 400-mesh copper grids (Agar Scientific, Essex, UK) for 1 min, and the excess was removed using filter paper. Subsequently the grid was washed using 4 μ l of Milli-Q water filtered with 0.22 μ m filter and blotted dry, then negatively stained twice with 4 μ l of filtered 2% (w/v) uranyl acetate for 1 min and blotted dry. The grid was allowed to air-dry before examination on a Hitachi 7100 transmission electron microscope (Hitachi, Germany) fitted with a Gatan Ultrascan 1000 CCD camera (Gatan, Abingdon, UK) at an operating voltage of 100 kV.

Dityrosine cross-linked A β 42 fibril stability

A β 42 was assembled under oxidizing and non-oxidizing conditions and stored at -80°C for more than one year and the dityrosine content was assessed using fluorescence with an excitation wavelength of 320 nm as described above. Both oxidized and non-oxidized A β 42 fibrils were centrifuged for 30 min at 16,000 RCF at 4°C, and then the soluble A β 42 concentration in the supernatant was measured using absorbance at 280 nm (as described for peptide preparation). TEM grids were prepared to examine the A β 42 fibrils in the pellet. The oxidized and non-oxidized fibrils were then dissolved in 80% v/v formic acid with agitation. The resulting solution was centrifuged using the same conditions above, and again the dissolved A β 42 concentration was determined. TEM grids for the pellet were prepared to examine the

morphology of the dissolved fibrils and to compare their density.

SDS gel electrophoresis

A β was incubated under oxidizing conditions as before for 10 mins and then quenched using EDTA. Oxidized and non-oxidized A β peptides were separated by SDS-PAGE and analyzed by densitometry. Samples were heated to 85°C for 5 min and then 5 μ l added to each well of a Novex® 1.0 mm 10-20% Tricine gel, (Life Technologies Ltd, Paisley, UK). Oxidized and nonoxidized samples were run on the XCell SureLock® Mini-Cell with a PowerEase® 500 power supply (Life Technologies Ltd, Paisley, UK). A voltage of 125 V, an expected start current of 80 mA/gel and an expected end current of 40 mA/gel was applied. The gel was stained using Silver-Quest™ Silver staining kit (Life Technologies Ltd, Paisley, UK) following the manufacturers protocol provided. Briefly, the gel was fixed for 60 min in 40% ethanol, 10% acetic acid, and 50% milliQ water, then rinsed in 30% ethanol (10 min), incubated in sensitizer solution (10 min), rinsed in 30% ethanol (10 min), washed with milliQ water (10 min), incubated in silver stain (15 min), and washed again with milliQ water (60 sec). The gel was then incubated in developer (5–10 min). Finally, the stopper was directly added to the stained gel (10 min) and subsequently washed with milliQ water (10 min). The gel was scanned at 8 bit with 600 dpi resolution. The densitometry was calculated using ImageJ.

Immunogold labeling, negative stain TEM (for fibrils and cerebrospinal fluid)

A modified phosphate-buffered saline, pH 8.2, containing 1% BSA, 500 μ l/l Tween-20, 10 mM Na EDTA, and 0.2 g/l NaN₃ (henceforward termed PBS+), was used throughout all the following procedures for all dilutions of antibodies and secondary gold probes. A β 42 fibrils were oxidized and assembled as described in oxidation of fibrillar and early oligomeric A β 42 and immunogold-labeled 'on grid' for dityrosine according to established methods. A monoclonal anti-dityrosine antibody was purchased from Japan Institute for the Control of Aging (JaICA) Shizuoka, Japan (cat. no. MDT-020P). The antibody has been fully characterised and shown to be highly specific and does not show any cross-reactivity

with other tyrosine derivatives such as nitrotyrosine, chlorotyrosine [31]. The antibody will detect any protein containing dityrosine. Briefly, 4 μ l aliquots of the oxidized A β 42 fibrils were pipetted onto Formvar/carbon coated 400 mesh copper TEM support grids (Agar Scientific, Essex, UK), left for 1 min, the excess was removed with filter paper, and then blocked in normal goat serum (1:10 in PBS+) for 15 min. Grids were then incubated with (10 μ g/ml IgG) mouse dityrosine monoclonal antibody (JaICA, Shizuoka, Japan) for 2 h at room temperature, rinsed in 3 \times 2 min PBS+, and then immunolabeled in a 10 nm gold particle-conjugated goat anti-mouse IgG secondary probe (GaM10 British BioCell International, Cardiff, UK; 1:10 dilution) for 1 h at room temperature. After 5 \times 2 min PBS+ and 5 \times 2 min distilled water rinses, the grids were negatively stained as described in negative stain TEM.

Cerebrospinal fluid (CSF) samples from AD patients and control age matched subjects were obtained from the London Neurodegenerative Diseases Brain Bank. CSF was removed according to Local Ethics Committee guidelines, and informed consent for brain donation was obtained from the next of kin (see Table 1). The samples were stored at -80°C in a locked freezer until needed. When required, they were diluted with Milli-Q water (1:3). A rabbit antibody raised against N-terminus of A β 42 (1–6) (AB5078P, Chemicon, Temecula, CA, USA) was used to detect A β in the following experiments. This antibody has been shown not to cross react with APP [32]. Diluted CSF samples were double-immunogold-labeled for dityrosine and A β 42 as described above, except grids were incubated in a mixture of (10 μ g/ml IgG) anti A β 42 rabbit polyclonal antibody AB5078P (Chemicon, Temecula, CA, USA) and (10 μ g/ml IgG) mouse monoclonal dityrosine antibody (Japan Institute for the Control of Aging JaICA, Shizuoka, Japan). A mixture of 5 nm gold particle-conjugated goat anti-rabbit IgG (GaR5 British BioCell International, Cardiff, UK) and 15 nm gold particle-conjugated GaM (British BioCell International, Cardiff, UK; 1:10 dilution) was used for the secondary gold probe.

Immunogold Labeling TEM of sections

AD and aged matched control brain from middle frontal gyrus tissues were obtained from London Neurodegenerative Diseases Brain Bank. Tissue was removed according

Table 1 Demographic details of cases from which cerebrospinal fluid were obtained

Case	Age	Sex	Pathological diagnosis
AD 1	68	M	Alzheimer's disease HP-tau stage 6 with mild to moderate amyloid angiopathy
AD 2	93	F	Alzheimer's disease HP-tau stage 6 with moderate amyloid angiopathy
AD 3	91	M	Alzheimer's disease HP-tau stage 6 with moderate amyloid angiopathy
Normal 1	89	F	Control case but with hypoxic-type changes and amyloid angiopathy
Normal 2	92	F	Control-some amyloid angiopathy

to Local Ethics Committee guidelines, and informed consent for brain donation was obtained from the next of kin (see Table 2) and stored at -80°C until required. SH-SY5Y cells were incubated for 24 hours with a final concentration of freshly prepared $10\text{ }\mu\text{M}$ A β 42 and controls cells were administered with buffer only (prepared as described in Soura *et al.*, 2012 [33]). SH-SY5Y cells and brain tissues were prepared for immunogold labeling TEM by minimal, cold fixation and embedding protocols, as previously described in Soura *et al.*, (2012) [33] and Thorpe *et al.*, (2001) [34], respectively. Immunogold labeling was performed using an established methodology [35], with PBS + buffer being used for all dilutions of immunoreagents and for rinsing. Thin sections were collected upon TEM support grids, then incubated with normal goat serum (1:10 dilution) for 30 min at room temperature to block non-specific secondary antibody binding. In turn, grids were labeled with ($10\text{ }\mu\text{g/ml}$ IgG) anti-dityrosine mouse monoclonal antibody (Japan Institute for the Control of Aging JaICA, Shizuoka, Japan) or double-labeled using a mixture of ($10\text{ }\mu\text{g/ml}$ IgG) anti-A β 42 rabbit polyclonal antibody AB5078P (Chemicon, Temecula, CA, USA) and ($10\text{ }\mu\text{g/ml}$ IgG) anti-dityrosine mouse monoclonal antibody and incubated overnight at 4°C . After $3\times 2\text{ min}$ PBS + rinses, sections were then immunolabeled with GaM10 or a mixture of GaR5 and GaM10 secondary probes (both 1:10 dilution), respectively, for 1 h at room temperature. After $3\times 10\text{ min}$ PBS + and $4\times 5\text{ min}$ distilled water rinses, the grids were post-stained in $0.22\text{ }\mu\text{m}$ -filtered 0.5% (w/v) aqueous uranyl acetate for 1 h. Labelling controls were performed using serial sections and using the identical procedure and IgG concentrations, with an irrelevant antibody to hair cell antigen (MAb10) (Richardson *et al.*, personal communication).

The grids were examined on a Hitachi 7100 TEM (Hitachi, Germany) fitted with a Gatan Ultrascan 1000 CCD camera (Gatan, Abingdon, UK), and operating with a voltage of 100 kV.

Analysis of immunogold labeled sections

Counting and size analyses of immunogold particles were performed using in house software written in Matlab.

Briefly, raw digital electron micrograph images files were uploaded and circular particles detected using in-built Matlab circular Hough transforms functions. The detection range diameter was calculated from user input and conversion to pixel size values read from the image header. 15 or 10 nm gold particles were distinguished from 5 nm particles based on a user-selected threshold of 7 nm.

Results

***In vitro* oxidation of A β 42 resulting in the formation of dityrosine cross-links**

A β 42 amyloid fibrils were preformed in water and incubated for up to three days in the presence of Cu^{2+} and H_2O_2 in phosphate buffer pH 7.4 to induce dityrosine cross-link formation by oxidation. The fibrils were examined using fluorescence spectrometry and an increasing signal at 400–420 nm corresponding to dityrosine [36] was observed with time of oxidation (Figure 1a). To further confirm the presence of dityrosine within the oxidized A β 42 fibrils, the fibrils (prepared in water) were hydrolyzed using 6 M HCl, 10% TFA, and 1% phenol for 48 h and examined using LC-ESIMS/MS (Figure 1b). The dityrosine content was identified using transition reactions ions 361.1/315 and a retention time of 5.5 min (Figure 1bii), consistent with that of a dityrosine standard (Figure 1bi). Negative stain transmission electron microscopy (TEM) was used to compare oxidized fibrils with non-oxidized fibrils to evaluate any potential morphological changes to the samples and revealed short, clumped networks of fibrils in the oxidized sample after 24 hours (Figure 1d) compared to long, straight, and well dispersed fibrils with diameter of 9.32 nm ($\text{SD} \pm 2.1\text{ nm}$, $n = 6$) observed in the sample without oxidation and incubated in phosphate buffer only (Figure 1c). This may suggest that the oxidized fibrils are cross-linked to form a network and this is consistent with tyrosine residue 10 being exposed on the surface of the fibrils and available for dityrosine crosslinking between either protofilaments or perhaps individually crossing fibrils. Structures for A β 42 and A β 40 fibrils show the tyrosine residue at position 10 at the end of β -sheet core [4,37] showing

Table 2 Demographic details of cases from which middle frontal gyrus tissues were obtained

Case	Age	Sex	Pathological diagnosis
Normal 1	89	F	Control case but with Hypoxic-type changes and amyloid angiopathy
Normal 3	80	F	Control-minimal ageing changes
AD 1	68	M	Alzheimer's disease HP-tau stage 6 with mild to moderate amyloid angiopathy
AD 2	93	F	Alzheimer's disease HP-tau stage 6 with moderate amyloid angiopathy
AD 3	91	M	Alzheimer's disease HP-tau stage 6 with moderate amyloid angiopathy
AD 4	86	F	Alzheimer's disease HP-tau stage 6 with mild amyloid angiopathy
AD 5	77	F	Alzheimer's disease -modified Braak BNE stage 5




Figure 1 Formation of dityrosine crosslinks in Aβ42 fibrils. Preformed Aβ42 fibrils (20 μM) were incubated in the presence of Cu²⁺/H₂O₂ for 72 hours and the appearance of dityrosine detected using fluorescence (**a**). **b** The dityrosine content was confirmed using LC-ESIMS/MS and this shown with relative abundance on y-axis. i) LC-ESIMS/MS from authentic synthetic dityrosine, ii) hydrolysate from oxidized preformed Aβ42 fibrils, iii) hydrolysate from Aβ42 fibrils formed under oxidation conditions for three days (the fibrils were obtained from incubation of soluble Aβ42 with Cu²⁺/H₂O₂ in water at 37°C and agitation) (**c**, **d**) Electron micrographs showing the morphology of fibrils prior to oxidation (**c**) and following 24 hour oxidation (**d**) (diameters approximately 100–150 Å).

that they may be available to be involved in lateral association.

Many recent studies have demonstrated that soluble Aβ oligomers, rather than Aβ fibrils, are the most toxic species and disruptive to physiological processes involved in learning and memory in AD [33,38,39]. Dimeric species have been isolated from AD brains [40] and these have also been shown to be toxic [41]. Oligomers formed by synthetic dityrosine crosslinked dimers have been shown to be more toxic than corresponding monomeric peptide [42]. In order to investigate whether dityrosine crosslinks can be formed by soluble Aβ42, freshly solubilized Aβ42 was incubated up to three days in the presence and absence of Cu²⁺ and H₂O₂ in phosphate buffer at pH 7.4 to induce crosslinking as well as to follow fibrillogenesis. Dityrosine formation was monitored using fluorescence excitation over three days (Figure 2a,b) and confirmed by LC-ESIMS/MS (Figure 1biii). The resulting

assemblies were also assessed using TEM, Thioflavin T (ThT) fluorescence and SDS-PAGE.

Fluorescence spectra revealed an increasing dityrosine fluorescence signal with time in the Aβ42 sample incubated in the presence of Cu²⁺ and H₂O₂ (Figure 2a), whilst no such signal was observed in the control sample (Figure 2b). To examine how quickly dityrosine cross-linking develops, the oxidized sample was monitored using fluorescence over one hour (Figure 2c) revealing the presence of dityrosine after only 10 minutes incubation. In contrast, at an excitation wavelength of 280 nm, the tyrosine fluorescence signal at 305 nm was observed to decrease over the incubation time of three days (Figure 2d). A gradual decrease in tyrosine intensity was observed for control fibrils (Figure 2d) and this decrease is thought to correspond to involvement of tyrosine residues in Aβ42 assembly [43] or could be due to loss of signal as the fibrils elongate and precipitate. Tyrosine




Figure 2 Monitoring dityrosine and tyrosine fluorescence during A β 42 assembly. Freshly prepared A β 42 (20 μ M) was incubated in the presence of Cu $^{2+}$ /H $_2$ O $_2$ and monitored by fluorescence over three days **(a)** and compared to A β 42 alone **(b)**. Dityrosine fluorescence was monitored (Ex. 320 nm, Em. 410–420 nm) and **a)** oxidized A β 42 shows a strong signal at 24 hours incubation compared to no signal in **(b)** control A β 42 sample. The development of the dityrosine signal was monitored at earlier time points **(c)** using the addition of EDTA and the spectrum shows a signal at 420 nm following only 10 mins incubation. Tyrosine fluorescence (Ex. 280 nm, Em. 305 nm) was used to follow assembly with time **(d)**. The intensity at 305 nm is plotted against time. Both conditions show a decrease in fluorescence signal over time for tyrosine, but oxidized A β 42 shows a significant reduction after 24 hours, compared to a slow reduction in tyrosine fluorescence that accompanies assembly for control A β 42.

fluorescence spectra revealed a very significant loss of tyrosine signal concurrent with the increase in dityrosine signal in the oxidized sample following 24 hours incubation (Figure 2d) at the same time as a strong dityrosine signal is observed. At time zero, the intensity at 305 nm is lower for the oxidized sample compared to control and this is arises from quenching of the signal due to binding of the Cu $^{2+}$ to tyrosine. Dityrosine formation appears to occur early (after only 10 mins) in the assembly process consistent with dityrosine coupling being present in early oligomeric species. A ThT fluorescence assay showed an increased signal following 72 hour incubation of both control and oxidized A β 42 confirming formation of fibrils in both samples (Figure 3a). However, the intensity of the signal from control fibrils is significantly higher than for oxidized fibrils. This may arise from the effect of differences in the buffer conditions on ThT signal or possibly due to the increased association of fibrils formed by oxidized A β 42 revealed by electron microscopy (Figure 4). Following only 10 minutes incubation, SDS gel electrophoresis separation of oxidized A β 42 reveals the presence of bands at molecular weights corresponding to dimer to hexamer (Figure 3b), similar to those shown by oxidation using PICUP [44], which supports the view that small A β assemblies can be stabilized by oxidation to dityrosine. In comparison, A β

incubated without oxidation runs as a monomer and a trimer, but no significant dimer is observed (Figure 3b). These SDS stable oligomeric species appear to evolve further and we observe fibrils following 48 incubation (Figure 4) suggesting that the formation of the cross-linked dimer could be on pathway for fibril assembly.

To gain further insight into the morphological changes to A β 42 fibrils induced by oxidation, samples were examined using negative stain TEM (Figure 4). A β 42 immediately following preparation (zero hour) showed small globular structures consistent with oligomeric species (5–30 nm) (Figure 4a and 4d). Under oxidation conditions the freshly dissolved A β 42 oligomers again appeared to have a spherical appearance (5–25 nm) (Figure 4a) and these developed into larger, non-fibrillar structures after 24 hours (Figure 4b) and then into clustered fibrils after 48 hours (Figure 4c). After incubation for 24 hours in phosphate buffer only, fibrils were observed with both flat, striated ribbons, and twisted morphologies (Figure 4e) and these developed further at 48 hours (Figure 4f). TEM did not reveal any obvious differences in fibril density between A β incubated under oxidizing and non-oxidizing conditions, although the oxidized sample appears to show shorter, more self-associated fibrils, which may be consistent with some interfibrillar crosslinking. Fibrils were observed following




Figure 3 Thioflavine T fluorescence and SDS PAGE of oxidized and control Aβ42. **a)** ThT fluorescence spectra following fibril formation from Aβ42 (20 μM) in the presence or absence of Cu²⁺ and H₂O₂ for 72 hours. The spectra for oxidized and control samples show an increased intensity over the incubation time and show increased ThT signal for non-oxidized compared to oxidized samples. **b)** SDS PAGE showing separation of Aβ42. Oxidized Aβ42 (left column) runs as monomer and dimer (approx. 9 kDa, black arrow), whilst non oxidized, control Aβ42 (right column) shows bands corresponding to monomer and trimer as previously observed [44]. The trimer is thought to be induced by SDS [44]. Densitometry confirms that monomer is the strongest band following by dimer for oxidized but not control fibrils. This reveals that the dimer is enriched under oxidation conditions.




Figure 4 Transmission electron microscopy images of freshly formed Aβ42 fibrils. 20 μM Aβ42 (pH 7.4) was incubated in the presence of Cu²⁺/H₂O₂ (**a, b, c**) and compared to 20 μM Aβ42 in phosphate buffer alone (pH 7.4) (**d, e, f**). Assembly was monitored by electron microscopy after incubation for (a and d) zero hours, (b and e) 24 hours and (c and f) 48 hours. Both oxidized and control Aβ42 samples show oligomeric species at zero hour (**a, d**) and fibrils following 48 hour incubation (**c, g**). However, at 24 hours (b and f) fibrils were observed in non-oxidized conditions (**f**), but no fibrils were observed in oxidised conditions (**b**). The presence of dityrosine was detected using immunogold labeling using a dityrosine specific antibody that labeled oxidized fibrils (**g**) but not control fibrils (**h**).

24 hour incubation in control samples, but not until 48 hours for the oxidized A β 42.

In order to examine whether dityrosine crosslinks can be detected within the amyloid fibrils and to show the dityrosine distribution, TEM immunogold labeling using a dityrosine specific monoclonal antibody was performed. Figure 4e shows anti-dityrosine labeling on A β 42 fibrils revealing gold distributed close to the fibrils grown in an oxidizing environment. Control A β 42 did not label with the dityrosine antibody (Figure 4f). Very strong evidence of dityrosine identity was provided using these specific monoclonal dityrosine antibodies and these clear differences between oxidized and control also provides evidence for the specificity of the antibody. We are not able to rule out formation of trityrosine, but this would be expected to further strengthen the fibrils. Mass-spectrometry data (Figure 1b) shows strong evidence for the presence of dityrosine. These *in vitro* findings suggest that conditions

similar to oxidative stress can promote the formation of dityrosine cross-links in self-assembling A β 42 samples resulting in a high density within the fibrils. Interestingly, no fibrils were observed in the oxidized sample at 24 hours by TEM (data not shown), although there is a very strong signal by dityrosine fluorescence (Figure 2a & c). This supports the view that dityrosine cross-links form early in the assembly process.

Dityrosine crosslinking may lend further stability to the already stable amyloid fibrils formed. To investigate this possibility, we compared the stability of oxidized and non-oxidized A β 42 amyloid fibrils. Fibrils were stored at -80°C for over one year. Following thawing, dityrosine content was assessed using fluorescence and oxidized fibrils were shown to still contain dityrosine crosslinks after prolonged freezing, whilst no dityrosine fluorescence was detected for non-oxidized, frozen fibrils (Figure 5a). Both sets of fibrils were examined by electron microscopy, and both




Figure 5 The stability of crosslinked fibrils. **a)** Oxidized and non-oxidized A β 42 fibrils were examined using dityrosine fluorescence after prolonged incubation at -80°C showing a strong intensity signal at 420 nm for oxidized but not non-oxidized fibrils. **b)** Formic acid was used to dissolve the fibrils and the concentration of A β 42 in solution was compared before and after formic acid dissolution for oxidized and non-oxidized fibrils. **c)** Electron micrographs of oxidized fibrils before and after formic acid treatment showing that the dityrosine crosslinked fibrils are resistant to formic acid. **d)** Electron micrographs of non-oxidized fibrils before and after formic acid treatment showing the fibrils are susceptible to damage by formic acid. Scale bars represent 0.2 μm .

contained fibrils (Figure 5c and d). Comparison of soluble A β 42 concentration in the supernatants indicated that there was more soluble A β in the oxidized samples (Figure 5b). The fibril pellets were treated with formic acid to dissolve fibrils and the amount of peptide released into the supernatant was compared between the oxidized and non-oxidized samples (Figure 5b). The concentration of A β found in the supernatant following formic acid treatment was very significantly lower in oxidized sample compared to the non-oxidized sample (0 versus 14.8 μ M), suggesting that the oxidized fibrils were resistant to dissolution with the acid (Figure 5b). Electron microscopy revealed that the oxidized fibrils were shortened, but remained at a broadly similar concentration when compared to amounts prior to oxidation. Those that had not been oxidized were narrower and much more difficult to find on the grid (Figure 5c and d). These results seem to support the view that the dityrosine crosslinking strengthens the fibrils and these fibrils become more resistant to acid dissolution following oxidation.

A β 42 is internalized into neuroblastoma cells and becomes dityrosine crosslinked

In previous work, we have shown that freshly prepared A β 42 can be internalized into SH-SY5Y neuroblastoma cells and accumulates over 24 hours in lysosomal compartments [33]. We were interested to investigate whether the A β 42 administered to these cells formed dityrosine

crosslinks during incubation in contact with neuroblastoma cells. Cells were treated in an identical way to previous experiments [33], administered with a final concentration of freshly solubilized 10 μ M A β 42 and incubated for 24 hours. Sectioned cells were co-labeled with the mouse monoclonal dityrosine antibodies and rabbit polyclonal A β antibodies for A β 42 fibrils. Previously, a monoclonal, conformational specific antibody was used to detect A β [33]. For the purpose of this study, secondary antibodies were 5 nm gold conjugated goat anti-rabbit IgG and 10 nm gold conjugated goat anti-mouse IgG, allowing the identification of both A β (5 nm) and dityrosine (10 nm) respectively in the sectioned cells and the opportunity to detect whether they co-localized. TEM of sectioned neuroblastoma cells treated with A β 42 confirms the appearance of internalized A β 42 concentrated in lysosomal regions (Figure 6a), as shown previously [33]. Close examination also showed that dityrosine and A β 42 were co-localized together inside the lysosomes (Figure 6a). Examination of control cells showed some labeling of dityrosine within lysosomes, but no co-localization with A β labeling (Figure 6b). Further investigation revealed the presence of fibrillar A β 42 around and within the cells, where the fibrils exhibited clear co-localization of dityrosine and A β (Figure 6c). This suggests that A β is cross-linked both inside and outside of the neuroblastoma cells. Occasionally extracellular A β was observed to be entering the cells at the plasma membrane (Figure 7) and again




Figure 6 Immunogold labeling TEM showing neuroblastoma cells treated with 10 μ M oligomeric A β . **a)** The images reveal dityrosine (10 nm) and A β 42 (5 nm) labeling within the lysosomes of treated cells. **b)** low level dityrosine labeling was observed within lysosomes in vehicle treated, control cells, but no A β labeling was observed. **c)** Cells were observed containing fibrillar A β labeled for both A β (5 nm) and dityrosine (10 nm). White arrows are used to highlight the fibrillar material. Inserts show magnified images for further clarity.




Figure 7 Electron micrographs of sections of A β 42 treated neuroblastoma cells showing immunogold labeling of A β (5 nm) and dityrosine (10 nm). The images reveal colabeled fibrils outside and also inside the cells and highlight internalization at the plasma membrane (top left panel). The figure shows magnified images in the bottom two panels for extra clarity.

these showed co-localization of A β and dityrosine labeling. Taken together, these results suggest that the externally administered A β 42 becomes oxidized during incubation in the cellular environment and that dityrosine crosslinked oligomers (and possibly fibrils) can be internalized into lysosomes.

The presence of dityrosine within plaques in AD brain

We have established that A β 42 is able to undergo oxidation leading to formation of dityrosine crosslinks *in vitro* and in a cellular environment. To determine the possible physiological relevance of dityrosine formation in the A β accumulation in AD brain, immunogold labeling TEM was carried out to detect any co-localization of A β and dityrosine in AD brain and compared to age matched control brain. Previously dityrosine has been detected and quantified in AD brain [5]. Using HPLC with electrochemical array detector (HPLC-ECD), dityrosine was quantified in four regions of the AD brain [5]. It was reported that dityrosine levels were elevated significantly in the hippocampus and neocortical regions of the AD brain. However, no previous study has successfully detected dityrosine in plaques, and no cellular localization study of dityrosine in human brain has been reported before. Immunogold labeling using anti-dityrosine antibody

was performed on brain sections taken from AD patients and control subjects (see Table 1), which revealed a high density of dityrosine within amyloid plaques in AD brain sections (Figure 8a and c). A control was performed using an irrelevant antibody (to hair cell antigen) at identical an IgG concentration and showed virtually no labeling (<1 gold particles/micron) (Figure 8b) compared to the serial section showing dityrosine/A β labeling of the same plaque in Figure 8a (showing 100 gold particles/micron²). Figure 8c shows images revealing the clear labeling of the fibrillar component of the amyloid plaques with the dityrosine antibody (Figure 8ciii), indicating that the fibrils themselves contain dityrosine. Double immunogold labeling TEM was also used to confirm that the amyloid plaques labeled with the anti-A β antibody as well as anti-dityrosine (Figure 8di and diii) and this is highlighted by processing of the images to show different sized labels in red and blue in Figure 8e. The numbers of large (dityrosine) and small (A β) gold particles were compared between the amyloid plaque area and areas around the plaques and showed a level of 100 and 90 gold particles/micron² for dityrosine and A β respectively over plaque areas. In comparison, the non-plaque areas showed only 2 gold particles/micron² for both labels. Two additional AD patient brains were also examined and these are shown in




Figure 8 Immunogold labeling TEM within amyloid plaques from AD brains. **a)** Shows double labeling using the dityrosine antibody and anti-A β antibody on an AD brain section and reveals very dense labeling of the amyloid plaques. This is compared to a serial section **b)** Showing single labelling using an irrelevant antibody against hair cell antigen (HCA) to show the specificity of the dityrosine labeling on plaques. This image shows virtually no gold labeling. **c)** Shows single labeling using the dityrosine antibody to reveal very clear labeling at increasing magnification (ci, cii and ciii) showing that the dityrosine labels fibrils in the plaques. **d)** Double labeling with anti-A β (5 nm) and anti-dityrosine (10 nm) confirms colocalisation of dityrosine with A β within amyloid plaques at increasing magnifications (di and dii). **e)** Shows the 10 nm labeling for dityrosine highlighted in red and 5 nm labeling for A β in blue. Inserts show magnified images for further clarity. **f)** and **g)** show additional examples of co-immunogold labeling in brain from additional patients.

Figure 8f and g and show very high density labeling over plaques. These results show the high density, specific localization of dityrosine within plaques (Figure 8) and strong evidence for colocalisation with A β , suggesting a potentially important role for dityrosine in amyloid accumulation in amyloid plaques.

Dityrosine as a potential biomarker of oxidative stress in AD

Given our results showing the colocalisation of antibodies against dityrosine and A β over amyloid fibrils deposited in Alzheimer's brains and images showing that neuroblastoma cells incubated with A β 42 show dityrosine-A β colocalisation over fibrillar material and in lysosomes, we were interested to see if dityrosine crosslinked A β could be identified in cerebrospinal fluid (CSF) and could therefore be a useful biomarker for Alzheimer's disease.

Here, TEM immunogold labeling for dityrosine was used to detect dityrosine and gain a general view of protein oxidation represented by dityrosine in CSF of AD and healthy age-matched control subjects. TEM immunogold colabeling/negative staining of CSF reveals a higher density of dityrosine and A β labeling in CSF taken from three AD patients (Table 1) (Figure 9a) compared to age matched controls (Table 1) (Figure 9b). Overall there was a much higher density of labeling for both A β and dityrosine in AD CSF compared to controls, highlighting the presence of A β and also showing the increased level of dityrosine crosslinked proteins in AD CSF. In the CSF from AD patients, two different areas of labeling were observed: those with low-density co-localization, and others showing high-density co-localisation of dityrosine and A β indicating that the A β found in CSF may contain dityrosine crosslinks, but also




Figure 9 Immunogold labeling TEM/negatively stain of cerebrospinal fluid from AD brains and age matched controls. a) A higher density of dityrosine (labeled with 15 nm) and Aβ (labeled with 5 nm) labeling was observed for CSF from an AD patient (top images) compared to **b)** age matched control. In CSF of AD patients, we can identify two different areas of labeling, low-density co-localization (□), and high density co-localization (○) of dityrosine and Aβ. We observe significant labeling levels for AD CSF compared to virtually no labeling in CSF from control patients. Inserts show magnified images for further clarity.


that other tyrosine containing proteins are cross-linked in AD CSF.

Discussion

Our results have shown that dityrosine crosslinks form in preformed Aβ₄₂ fibrils and in oligomeric Aβ incubated under oxidizing conditions in the presence of Cu²⁺ and H₂O₂. We have also confirmed that the dityrosine crosslinked Aβ has the capability to assemble further to form amyloid fibrils. It has been shown previously that 1:1 Cu²⁺: Aβ molar ratios and above are the most efficient ratios to form dityrosine cross-links [45], demonstrating that Cu²⁺: Aβ molar ratio is a critical factor in controlling the aggregation state of Aβ₄₂. We have shown that oxidized Aβ forms stabilized dimer and tetramer and these might represent small oligomeric species that are isolated from AD brain [41]. We hypothesise that the brain derived dimer may be stabilized by dityrosine crosslinks [41,42] and work is on going to confirm this. Here we show that fibrils are stabilized by dityrosine crosslinking. Moreover, it has been shown that sub-stoichiometric Aβ₄₂-Cu²⁺ (10:1) complexes can be toxic to cells [46] and recent work has shown that non-aged and aged molar ratios of 1:1 Aβ₄₂-Cu²⁺ are neurotoxic, whilst Aβ₄₂-Cu²⁺ complexes prepared at sub and supra-equimolar ratios were nontoxic to neuronal cells [22,45]. Aβ peptide can coordinate with

Cu²⁺ to give Aβ-Cu²⁺ complexes [47,48], which are redox-active. In turn, these complexes show ability to induce ROS formation, resulting in oxidative stress [16,22]. Cu²⁺ ions coordinate to Aβ via the three histidine residues His6, His13, and His14 to form a histidine bridge [17,49-51] and produce SDS-resistant oligomers [20]. Recent work has shown that Tyr10 is not directly bound to Cu²⁺ [51] but that the tyrosine cross-linking is promoted by the histidine bridge formation with Cu²⁺ [22]. Taken together, we suggest that dityrosine crosslinking of Aβ could be nucleus for assembly and aggregation to form toxic oligomeric species and amyloid fibrils (Figure 10). An alternative route to dityrosine formation is via myeloperoxidase [52], a peroxidase shown to be associated with Aβ in senile plaques in AD brain tissue [53].

Here, cell culture experiments show that conditions amenable to Aβ dityrosine crosslinking are also present in a cellular environment and that dityrosine crosslinked Aβ fibrils are found around cells and internalized into cells. Aβ and dityrosine co-localize within lysosomes. In previous work, we have shown that internalized oligomeric Aβ₄₂ leads to accumulation of autophagosomes containing Aβ. Considerable evidence supports the view that intralysosomal Aβ accumulation can induce neuronal death [54-56] and here we have shown that oligomers and fibrils can be stabilized by dityrosine crosslinking. Studies using Aβ₄₂ with the tyrosine 10 substituted for alanine



mutant showed significantly reduced H₂O₂ production and prevented toxicity to primary cortical neurons supporting the view that dityrosine crosslinking may be important in mediating oligomer toxicity [57]. Here, electron micrographs show the internalization of dityrosine cross-linked Aβ fibrillar material into the cytoplasm (Figure 7) and into lysosomes (Figure 6). The oligomeric Aβ may be stabilized by covalent crosslinks and provide a stable nucleus for assembly (Figure 10).

Oxidative stress has been widely implicated in AD pathogenesis. Sources of ROS, such as H₂O₂, superoxide anion, and hydroxyl radical, can be formed from different *in vivo* sources (e.g. trace metals, photochemical, and enzymatic reactions) although mitochondria represent the main *in vivo* source of ROS formation [58]. At the same time mitochondria are the main target of ROS attack [59], resulting in the formation of peroxidized, undegradable macromolecules. H₂O₂ can easily diffuse into lysosomes and react with iron ions that are released from the degradation of different metalloproteins during their intralysosomal degradation. The interaction of H₂O₂ with iron ions results in the formation of the highly reactive hydroxyl radicals. The latter would attack intralysosomal macromolecules, such as Aβ, causing cross-linking of these materials. The oxidative modification especially cross-linking of autophagocytosed material, is the most probable cause of non-degradability of these materials. The excessive accumulation of these non-digested materials could result in endosomal/lysosomal

leakage and as a consequent acid hydrolase enzymes will be released and ultimately leading to cell death [56]. Recently, Murakami and Shimizu have clarified the role of cytoplasmic superoxide radical as a possible contributing factor to intracellular Aβ oligomerization in AD [60]. It also has been suggested that intraneuronal Aβ oligomers cause neuronal death by activating endoplasmic reticulum stress, endosomal/lysosomal leakage and mitochondria dysfunction [61,62]. Kurz et al., (2008) [63] have highlighted a close relation between lysosomes and mitochondria, explaining that accumulation of iron inside mitochondria will result in lysosomal iron loading as a consequence of degradation of mitochondria by lysosomal enzymes. Moreover, normal production of H₂O₂ by mitochondria results in oxidative stress, which will labilize lysosomes, and further oxidative stress could result from degradation of mitochondria by lysosomal enzymes.

We have shown that amyloid plaques in AD brain tissue show extensive dityrosine crosslinking and this may suggest that these highly stable insoluble deposits are stabilized by the covalent crosslinking resulting in a resistance to degradation. Therefore, the existence of dityrosine may be relevant in AD pathology. Friedrich et al., (2010) [64] have shown that Aβ internalized to cultured cells can accumulate and assemble resulting in eventual cell death and thus they suggest that the formation of amyloid plaques might arise from accumulated intracellular Aβ. Therefore, there may be a pathway from the

lysosomal/autophagosome accumulation of dityrosine crosslinked A β that we have observed in neuroblastoma cells to the eventual deposition as amyloid plaques composed of dityrosine crosslinked A β observed here in AD tissue. Previous work has revealed that dimeric (9 kDa) A β can be isolated from human AD brain [65] and this may be a crosslinked dimer. In future work, it would be important to fully characterize these dimers.

Clioquinol is a potent Cu/Zn chelator and has been shown to significantly reduce A β amyloid deposition in an APP transgenic mouse [66] and has shown some efficacy in human AD subjects [67]. These studies have been taken to suggest that copper plays a very significant role in A β deposition in AD and could imply that dityrosine formation can stabilize deposits.

A few studies have previously attempted to quantify dityrosine in cerebrospinal fluid. Techniques including HPLC with electrochemical array detection (HPLC-ECD) or fluorescence detection, and liquid chromatography with triple quadrupole mass spectrometric detection (LC-MS/MS) have been applied to quantify dityrosine concentrations in CSF sample from both healthy and disease affected subjects [5,68,69]. However, the results of these studies have been conflicting, perhaps due to differences in sample handling and preparation before measuring. Quantitative screening of protein glycation, oxidation and nitration adducts in CSF of AD and healthy age-matched subjects has been taken to suggest that dityrosine concentration do not change in AD patients with respect to control subjects [68]. By contrast, earlier studies using electrochemical detection showed that dityrosine concentration was elevated markedly in CSF of AD patients [5]. Studies have suggested that CSF is depleted of A β in AD patients, however, careful consideration of the results shows highly variable amounts of A β in CSF from patients [70]. Here we clearly show, using a specific antibody against the free N-terminus of A β 42, that A β more abundant within AD CSF relative to the age matched controls.

Our results have revealed very strong evidence for the presence of both A β and dityrosine in CSF from AD patients and both A β and dityrosine are very rarely observed in CSF from age-matched controls. Although this observation needs to be further substantiated with further AD cases, this points to the possible use as a potential biomarker for AD.

Conclusions

At equimolar ratio of Cu²⁺ and A β 42, Cu²⁺ can catalyze tyrosine oxidation by H₂O₂, leading to dityrosine cross-link generation, and the latter can cause A β misfolding, resulting in A β assembly into oligomers and subsequently into amyloid fibres. The dityrosine cross-links stabilize A β fibres once formed.

Here we present a comprehensive study of *in vivo* and *in vitro* dityrosine cross-linking associated with A β . We have revealed the presence of dityrosine cross-links in amyloid plaques in human AD brain, and also in CSF, and identified significant relationships between dityrosine cross-links and amyloid deposit formation. The *in vitro* and *in vivo* results presented here reveal that oligomeric A β can undergo oxidative modification in a cellular environment, resulting in cross-linked A β through dityrosine followed by intralysosomal A β accumulation that could lead to lysosomal leakage and cell death. Our results show the significant accumulation of dityrosine crosslinked A β in amyloid plaques, implying a role in stabilization of these insoluble deposits. We have also shown a potential biomarker for AD in CSF, which contains elevated dityrosine crosslinked proteins as well as elevated dityrosine cross-linked A β (Figure 9). Research is ongoing to further characterize the crosslinked A β as a biomarker in CSF.

Competing interest

The authors declare that they have no competing interest.

Authors' contributions

YA-H conducted and analyzed the experiments and wrote the paper. TW designed experiments, TW, MS-P, ES, LF, MC, WGB conducted experiments, KLM contributed to data analysis, AA-S contributed to experimental design and writing of the paper, JT conducted experiments and analysis and wrote the paper, LCS managed the research and wrote the paper. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by funding from Alzheimer's research UK and Biotechnology and Biological Sciences Research Council, UK. YA is supported by funding Ministry of Higher Education and Scientific Research in Iraq. The authors would like to acknowledge help with synthesis and characterisation of dityrosine from Dr Matthew Stanley, Dr Iain Day and Prof. Mark Bagley. Brain tissue was provided by the London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, King's College, London, and, respectfully, we thank the anonymous tissue donors and their next of kin. The authors thank Prof. Guy Richardson and Dr Richard Goodyear for MAb10 antibody.

Author details

¹School of Life Sciences, University of Sussex, Falmer BN1 9QG, UK. ²College of Sciences, Chemistry department, Al-Mustansiriyah University, Baghdad, Iraq. ³Physics Department, Drexel University, Philadelphia PA 19104, USA. ⁴Current address: School of Life Sciences, Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, UK.

Received: 3 December 2013 Accepted: 7 December 2013

Published: 18 December 2013

References

1. Selkoe DJ: The molecular pathology of Alzheimer's disease. *Neuron* 1991, **6**:487–498.
2. Rambaran RN, Serpell LC: Amyloid fibrils: abnormal protein assembly. *Prion* 2008, **2**:112–117.
3. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 2002, **297**:353–356.
4. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, Schubert D, Riek R: 3D structure of Alzheimer's amyloid-beta(1–42) fibrils. *Proc Natl Acad Sci USA* 2005, **102**:17342–17347.
5. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA: Electrochemical analysis of protein nitrotyrosine and dityrosine in the

- Alzheimer brain indicates region-specific accumulation. *J Neurosci* 1998, **18**:8126–8132.
6. Bush AI, Curtain CC: Twenty years of metallo-neurobiology: where to now? *Eur Biophys J* 2008, **37**:241–245.
 7. Ali FE, Barnham KJ, Barrow CJ, Separovic F: Copper catalysed oxidation of amino acids and Alzheimer's disease. *Lett Pept Sci* 2003, **10**:405–412.
 8. Sarell CJ, Wilkinson SR, Viles JH: Substoichiometric levels of Cu²⁺ ions accelerate the kinetics of fiber formation and promote cell toxicity of amyloid- $\text{CE} \leq$ from Alzheimer disease. *J Biol Chem* 2010, **285**:41533–41540.
 9. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT: Redox-active metals, oxidative stress, and Alzheimer's disease pathology. *Ann NY Acad Sci* 2004, **1012**:153–163.
 10. Bush AI: The metallobiology of Alzheimer's disease. *Trends Neurosci* 2003, **26**:207–214.
 11. Levine RL, Stadtman ER: Oxidative modification of proteins during aging. *Exp Gerontol* 2001, **36**:1495–1502.
 12. Lynch T, Cherny RA, Bush AI: Oxidative processes in Alzheimer's disease: the role of A β -metal interactions. *Exp Gerontol* 2000, **35**:445–451.
 13. Butterfield DA, Reed T, Newman SF, Sultana R: Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. *Free Radic Biol Med* 2007, **43**:658–677.
 14. Double KL, Dedov VN, Fedorow H, Kettle E, Halliday GM, Garner B, Brunk UT: The comparative biology of neuromelanin and lipofuscin in the human brain. *Cell Mol Life Sci* 2008, **65**:1669–1682.
 15. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR: Copper, iron and zinc in Alzheimer's disease senile plaques. *J Neurol Sci* 1998, **158**:47–52.
 16. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, et al: The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. *Biochemistry-Us* 1999, **38**:7609–7616.
 17. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NME, Romano DM, Hartshorn MA, Tanzi RE, Bush AI: Dramatic aggregation of Alzheimer ACE \leq by Cu(II) is induced by conditions representing physiological acidosis. *J Biol Chem* 1998, **273**:12817–12826.
 18. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H: Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrate and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. *J Biol Chem* 2000, **275**:18344–18349.
 19. Yoburn JC, Tian W, Brower JO, Nowick JS, Glabe CG, Van Vranken DL: Dityrosine cross-linked Abeta peptides: fibrillar beta-structure in Abeta (1–40) is conducive to formation of dityrosine cross-links but a dityrosine cross-link in Abeta(8–14) does not induce beta-structure. *Chem Res Toxicol* 2003, **16**:531–535.
 20. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, Huang X, Moir RD, Wang D, Sayre LM, et al: Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. *Biochemistry-Us* 2004, **43**:560–568.
 21. Giulivi C, Traaseth NJ, Davies KJ: Tyrosine oxidation products: analysis and biological relevance. *Amino Acids* 2003, **25**:227–232.
 22. Smith DP, Smith DG, Curtain CC, Boas JF, Pilbrow JR, Ciccotosto GD, Lau TL, Tew DJ, Perez K, Wade JD, et al: Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. *J Biol Chem* 2006, **281**:15145–15154.
 23. DiMarco T, Giulivi C: Current analytical methods for the detection of dityrosine, a biomarker of oxidative stress, in biological samples. *Mass Spectrom Rev* 2007, **26**:108–120.
 24. Amado R, Aeschbach R, Neukom H: Dityrosine - invitro production and characterization. *Methods Enzymol* 1984, **107**:377–388.
 25. Giulivi C, Davies KJ: Dityrosine: a marker for oxidatively modified proteins and selective proteolysis. *Methods Enzymol* 1994, **233**:363–371.
 26. Guo ZW, Salamoneczyk GM, Han K, Machiya K, Sih CJ: Enzymatic oxidative phenolic coupling. *J Org Chem* 1997, **62**:6700–6701.
 27. Lee DI, Hwang S, Choi JY, Ahn IS, Lee CH: A convenient preparation of dityrosine via Mn(III)-mediated oxidation of tyrosine. *Process Biochem* 2008, **43**:999–1003.
 28. Skaff O, Loffliffe KA, Hutton CA: Synthesis of the side chain cross-linked tyrosine oligomers dityrosine, trityrosine, and pulcherosine. *J Org Chem* 2005, **70**:7353–7363.
 29. Jacob JS, Cistola DP, Hsu FF, Muzaffar S, Mueller DM, Hazen SL, Heinecke JW: Human phagocytes employ the myeloperoxidase-hydrogen peroxide system to synthesize dityrosine, trityrosine, pulcherosine, and isodityrosine by a tyrosyl radical-dependent pathway. *J Biol Chem* 1996, **271**:19950–19956.
 30. Williams TL, Day U, Serpell LC: The effect of Alzheimer's Abeta aggregation state on the permeation of biomimetic lipid vesicles. *Langmuir* 2010, **26**:17260–17268.
 31. Kato Y, Wu X, Naito M, Nomura H, Kitamoto N, Osawa T: Immunochemical detection of protein dityrosine in atherosclerotic lesion of apo-E-deficient mice using a novel monoclonal antibody. *Biochem Biophys Res Commun* 2000, **275**:11–15.
 32. Agholme L, Hallbeck M, Benedikz E, Marcusson J, Kagedal K: Amyloid-beta secretion, generation, and lysosomal sequestration in response to proteasome inhibition: involvement of autophagy. *J Alzheimers Dis* 2012, **31**:343–358.
 33. Soura V, Stewart-Parker M, Williams TL, Ratnayaka A, Atherton J, Gorrington K, Tuffin J, Darwent E, Rambaran R, Klein W, et al: Visualization of co-localization in Abeta42-administered neuroblastoma cells reveals lysosome damage and autophagosome accumulation related to cell death. *Biochem J* 2012, **441**:579–590.
 34. Thorpe JR, Morley SJ, Rulten SL: Utilizing the peptidyl-prolyl cis-trans isomerase Pin1 as a probe of its phosphorylated target proteins: Examples of binding to nuclear proteins in a human kidney cell line and to tau in Alzheimer's diseased brain. *J Histochem Cytochem* 2001, **49**:97–107.
 35. Thorpe JR: The application of LR gold resin for immunogold labeling. *Methods Mol Biol* 1999, **117**:99–110.
 36. Malencik DA, Sprouse JF, Swanson CA, Anderson SR: Dityrosine: Preparation, isolation, and analysis. *Anal Biochem* 1996, **242**:202–213.
 37. Paravastu AK, Leapman RD, Yau WM, Tycko R: Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. *Proc Natl Acad Sci USA* 2008, **105**:18349–18354.
 38. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB: Amyloid $\text{CE} \leq$ -protein assembly and Alzheimer disease. *J Biol Chem* 2009, **284**:4749–4753.
 39. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid $\text{CE} \leq$ protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* 2002, **416**:535–539.
 40. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE: Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. *J Biol Chem* 1996, **271**:4077–4081.
 41. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al: Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nature medicine* 2008, **14**:837–842.
 42. Kok WM, Cottam JM, Ciccotosto GD, Miles LA, Karas JA, Scanlon DB, Roberts BR, Parker MW, Cappai R, Barnham KJ, Hutton CA: Synthetic dityrosine-linked beta-amyloid dimers form stable, soluble neurotoxic oligomers. *Chem Sci* 2013, **4**:4449–4454.
 43. Marshall KE, Serpell LC: Structural integrity of beta-sheet assembly. *Biochem Soc Trans* 2009, **37**:671–676.
 44. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB: Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. *Proc Natl Acad Sci USA* 2003, **100**:330–335.
 45. Smith DP, Ciccotosto GD, Tew DJ, Fodero-Tavoletti MT, Johanssen T, Masters CL, Barnham KJ, Cappai R: Concentration dependent Cu²⁺ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. *Biochemistry-Us* 2007, **46**:2881–2891.
 46. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JDA, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, et al: Cu(II) Potentiation of Alzheimer A β Neurotoxicity: CORRELATION WITH CELL-FREE HYDROGEN PEROXIDE PRODUCTION AND METAL REDUCTION. *J Biol Chem* 1999, **274**:37111–37116.
 47. Syme CD, Nadal RC, Rigby SE, Viles JH: Copper binding to the amyloid-beta (Abeta) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Abeta-(1–28): insights from a range of complementary spectroscopic techniques. *J Biol Chem* 2004, **279**:18169–18177.
 48. Atwood CS, Scarpa RC, Huang XD, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI: Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta 1–42. *J Neurochem* 2000, **75**:1219–1233.

49. Tickler AK, Smith DG, Ciccotosto GD, Tew DJ, Curtain CC, Carrington D, Masters CL, Bush AI, Cherny RA, Cappai R, et al: **Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity.** *J Biol Chem* 2005, **280**:13355–13363.
50. Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, Barnham KJ: **Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits.** *J Biol Chem* 2001, **276**:20466–20473.
51. Maiti NC, Jiang DL, Wain AJ, Patel S, Dinh KL, Zhou FM: **Mechanistic studies of Cu(II) binding to amyloid-beta peptides and the fluorescence and redox behaviors of the resulting complexes.** *J Phys Chem B* 2008, **112**:8406–8411.
52. Marquez LA, Dunford HB: **Kinetics of oxidation of tyrosine and dityrosine by myeloperoxidase compounds I and II. Implications for lipoprotein peroxidation studies.** *J Biol Chem* 1995, **270**:30434–30440.
53. Reynolds WF, Rhee S, Maciejewski D, Paladino T, Sieburg H, Maki RA, Masliah E: **Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease.** *Exp Neurol* 1999, **155**:31–41.
54. Zheng L, Roberg K, Jerhammar F, Marcussen J, Terman A: **Autophagy of amyloid beta-protein in differentiated neuroblastoma cells exposed to oxidative stress.** *Neurosci Lett* 2006, **394**:184–189.
55. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, et al: **Macroautophagy—a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease.** *J Cell Biol* 2005, **171**:87–98.
56. Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG: **Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid A beta 1–42 pathogenesis.** *J Neurosci Res* 1998, **52**:691–698.
57. Barnham KJ, Haeflner F, Ciccotosto GD, Curtain CC, Tew D, Mavros C, Beyreuther K, Carrington D, Masters CL, Cherny RA, et al: **Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid.** *FASEB J* 2004, **18**:1427–1429.
58. Chance B, Sies H, Boveris A: **Hydroperoxide metabolism in mammalian organs.** *Physiol Rev* 1979, **59**:527–605.
59. Harman D: **Aging: a theory based on free radical and radiation chemistry.** *Sci Aging Knowledge Environ* 2002, **2002**:cp14.
60. Murakami K, Shimizu T: **Cytoplasmic superoxide radical: a possible contributing factor to intracellular Abeta oligomerization in Alzheimer disease.** *Comm Integ Biol* 2012, **5**:255–258.
61. Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, Mori H: **Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo.** *J Neurosci Res* 2011, **89**:1031–1042.
62. Misonou H, Morishima-Kawashima M, Ihara Y: **Oxidative stress induces intracellular accumulation of amyloid CE₁–protein (ACE₁) in human neuroblastoma cells.** *Biochemistry-U S A* 2000, **39**:6951–6959.
63. Kurz T, Terman A, Gustafsson B, Brunk UT: **Lysosomes and oxidative stress in aging and apoptosis.** *Biochim Biophys Acta Gen Subj* 2008, **1780**:1291–1303.
64. Friedrich RP, Tepper K, Ronicke R, Soom M, Westermann M, Reymann K, Kaether C, Fandrich M: **Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity.** *Proc Natl Acad Sci USA* 2010, **107**:1942–1947.
65. Roher AE, O'Chaney M, Kuo Y, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, et al: **Morphology and toxicity of Ab-(1–42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease.** *J Biol Chem* 1996, **271**:20631–20635.
66. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim YS, et al: **Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.** *Neuron* 2001, **30**:665–676.
67. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, et al: **Metal-protein attenuation with iodocholesterolhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.** *Arch Neurol* 2003, **60**:1685–1691.
68. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Munch G: **Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment.** *J Neurochem* 2005, **92**:255–263.
69. Abdelrahim M, Morris E, Carver J, Facchina S, White A, Verma A: **Liquid chromatographic assay of dityrosine in human cerebrospinal fluid.** *J Chromatogr B* 1997, **696**:175–182.
70. Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H: **Cerebrospinal fluid amyloid beta(1–42) levels in the mild cognitive impairment stage of Alzheimer's disease.** *Exp Neurol* 2001, **172**:433–436.

doi:10.1186/2051-5960-1-83

Cite this article as: Al-Hilaly et al.: A central role for dityrosine crosslinking of Amyloid-β in Alzheimer's disease. *Acta Neuropathologica Communications* 2013 **1**:83.

Submit your next manuscript to BioMed Central and take full advantage of:

- **Convenient online submission**
- **Thorough peer review**
- **No space constraints or color figure charges**
- **Immediate publication on acceptance**
- **Inclusion in PubMed, CAS, Scopus and Google Scholar**
- **Research which is freely available for redistribution**

Submit your manuscript at
www.biomedcentral.com/submit

